Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis
Authors:
- 18 December 1998
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (1) , 1-24
Abstract
No abstract availableKeywords
This publication has 206 references indexed in Scilit:
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Cyclization by a Specific Lactam Increases the Ability of Human Parathyroid Hormone (hPTH)-(1–31)NH2 to Stimulate Bone Growth in Ovariectomized RatsJournal of Bone and Mineral Research, 1997
- A realistic clinical perspective of tamoxifen and endometrial carcinogenesisEuropean Journal of Cancer, 1996
- Cloning of a novel receptor expressed in rat prostate and ovary.Proceedings of the National Academy of Sciences, 1996
- A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenJournal of Bone and Mineral Research, 1996
- On fluoride and bone strengthCalcified Tissue International, 1993
- Hip fractures in the elderly: A world-wide projectionOsteoporosis International, 1992
- Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the ratJournal of Steroid Biochemistry, 1990
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990
- Non-isomerisable antiestrogens related to tamoxifenJournal of Steroid Biochemistry, 1988